6 investors discuss why AI is more than just a buzzword in biotech
TechCrunch
DECEMBER 15, 2022
“Most of the companies we have seen have an AI component to support the discovery or development processes,” Francisco Dopazo, a general partner at Humboldt Fund told TechCrunch recently. When evaluating ‘AI for drug discovery companies,’ I view AI as a tool,” Shaq Vayda, principal at Lux Capital, told TechCrunch.
Let's personalize your content